Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 3
1986 1
1987 1
1991 1
1992 3
1993 1
1997 1
1998 1
2004 1
2009 1
2010 1
2013 3
2014 2
2018 1
2019 4
2020 1
2021 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

25 results

Results by year

Filters applied: . Clear all
Page 1
India ink: a time-tested histological marker.
Boezaart A, Sala-Blanch X, Monzo E, Reina MA. Boezaart A, et al. Among authors: monzo e. Reg Anesth Pain Med. 2019 Apr 16:rapm-2019-100553. doi: 10.1136/rapm-2019-100553. Online ahead of print. Reg Anesth Pain Med. 2019. PMID: 30992409 No abstract available.
Review of Classification Systems for Adult Acquired Flatfoot Deformity/Progressive Collapsing Foot Deformity and the Novel Development of the Triple Classification Delinking Instability/Deformity/Reactivity and Foot Type.
Pasapula CS, Choudkhuri MR, Monzó ERG, Dhukaram V, Shariff S, Pasterse V, Richie D, Kobezda T, Solomou G, Cutts S. Pasapula CS, et al. Among authors: monzo erg. J Clin Med. 2024 Feb 6;13(4):942. doi: 10.3390/jcm13040942. J Clin Med. 2024. PMID: 38398256 Free PMC article. Review.
Follicular mucinosis and Hodgkin's disease.
Ramon D, Jorda E, Molina I, Galan A, Torres V, Alcacer J, Monzo E. Ramon D, et al. Among authors: monzo e. Int J Dermatol. 1992 Nov;31(11):791-2. doi: 10.1111/j.1365-4362.1992.tb04246.x. Int J Dermatol. 1992. PMID: 1428432 No abstract available.
Rituximab maintenance after first-line therapy with rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) for chronic lymphocytic leukemia.
Abrisqueta P, Villamor N, Terol MJ, González-Barca E, González M, Ferrà C, Abella E, Delgado J, García-Marco JA, González Y, Carbonell F, Ferrer S, Monzó E, Jarque I, Muntañola A, Constants M, Escoda L, Calvo X, Bobillo S, Montoro JB, Montserrat E, Bosch F. Abrisqueta P, et al. Among authors: monzo e. Blood. 2013 Dec 5;122(24):3951-9. doi: 10.1182/blood-2013-05-502773. Epub 2013 Oct 11. Blood. 2013. PMID: 24124086 Free article. Clinical Trial.
Rituximab, fludarabine, cyclophosphamide, and mitoxantrone: a new, highly active chemoimmunotherapy regimen for chronic lymphocytic leukemia.
Bosch F, Abrisqueta P, Villamor N, Terol MJ, González-Barca E, Ferra C, González Diaz M, Abella E, Delgado J, Carbonell F, García Marco JA, Escoda L, Ferrer S, Monzó E, González Y, Estany C, Jarque I, Salamero O, Muntañola A, Montserrat E. Bosch F, et al. Among authors: monzo e. J Clin Oncol. 2009 Sep 20;27(27):4578-84. doi: 10.1200/JCO.2009.22.0442. Epub 2009 Aug 24. J Clin Oncol. 2009. PMID: 19704063 Clinical Trial.
25 results